Tech Company Financing Transactions

Cedilla Therapeutics Funding Round

Janus Henderson Investors, Logos Capital and RA Capital participated in a $25 million Series B funding round for Cedilla Therapeutics. The financing round was announced on 10/26/2021.

Transaction Overview

Announced On
10/26/2021
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Proceeds Purpose
Proceeds from the financing will support Cedilla's continued growth and development of its two lead programs, an inhibitor of TEAD for the treatment of solid tumors, such as mesothelioma and certain squamous cell carcinomas, and a highly selective inhibitor of CDK2/Cyclin E for the treatment of multiple tumor types, including CDK4/6-resistant breast cancer, ovarian, uterine, stomach and esophageal cancers.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
245 1st St. 3rd Floor
Cambridge, MA 02142
USA
Phone
Undisclosed
Email Address
Overview
Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla's integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action.
Profile
Cedilla Therapeutics LinkedIn Company Profile
Social Media
Cedilla Therapeutics Company Twitter Account
Company News
Cedilla Therapeutics News
Facebook
Cedilla Therapeutics on Facebook
YouTube
Cedilla Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Alexandra Glucksmann
  Alexandra Glucksmann LinkedIn Profile  Alexandra Glucksmann Twitter Account  Alexandra Glucksmann News  Alexandra Glucksmann on Facebook
Chief Scientific Officer
Brian Jones
  Brian Jones LinkedIn Profile  Brian Jones Twitter Account  Brian Jones News  Brian Jones on Facebook
Vice President
Delphine Collin
  Delphine Collin LinkedIn Profile  Delphine Collin Twitter Account  Delphine Collin News  Delphine Collin on Facebook
Vice President
Josh Murtie
  Josh Murtie LinkedIn Profile  Josh Murtie Twitter Account  Josh Murtie News  Josh Murtie on Facebook
Vice President
Eric Schwartz
  Eric Schwartz LinkedIn Profile  Eric Schwartz Twitter Account  Eric Schwartz News  Eric Schwartz on Facebook
VP - Bus. Development
Véronique Riethuisen
  Véronique Riethuisen LinkedIn Profile  Véronique Riethuisen Twitter Account  Véronique Riethuisen News  Véronique Riethuisen on Facebook
VP - Finance
Christopher Lindblom
  Christopher Lindblom LinkedIn Profile  Christopher Lindblom Twitter Account  Christopher Lindblom News  Christopher Lindblom on Facebook
VP - Human Resources
Justin Birtz
  Justin Birtz LinkedIn Profile  Justin Birtz Twitter Account  Justin Birtz News  Justin Birtz on Facebook


 

 

Browse more venture capital transactions:

Prev: 10/26/2021: Workit Health venture capital transaction
Next: 10/26/2021: Egle Therapeutics venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We do our best to record tech company VC transactions. All VC database entries on this site are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary